Financials

Ideas Discussions Technicals Seasonals

RGRX fundamentals

Overview Statements Statistics Dividends Earnings Revenue

Key facts

—

—

—

—

—

—

—

—

About

RegeneRx Biopharmaceuticals, Inc. engages in the development of a novel therapeutic peptide, Thymosin beta 4 for tissue and organ protection, repair, and regeneration. Its product pipeline includes RGN-259, RGN-352, and RGN-137. The company was founded by Allan L. Goldstein on May 13, 1982 and is headquartered in Rockville, MD.

Valuation

Fundamental metrics to determine fair value of the stock

Summary

No data available

There's currently no market capitalization, revenue or net income data to show.

Valuation ratios

Growth and Profitability

Company’s recent performance and margins

Dividends

Dividend yield, history and sustainability

RGRX does not pay dividends

The company has not previously paid dividends and at the moment there is no information about whether it is going to pay them in the future

Financial health

Financial position and solvency of the company